J&J to emphasize cancer drugs, stop much of its vaccine research

DanielHulshizer/APEightmonthsintohistenure,Johnson&Johnson’sR&Dchiefisputtingabigemphasisonm MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending




fashion

author：explore    Page View：773
Michel Pairet -- health business coverage from STAT
Michel Pairet Courtesy Boehringer Ingelheim

LONDON — At an event here last week, the German pharmaceutical firm Boehringer Ingelheim outlined the projects in its pipeline. 

There was obesity and liver disease, and computational biology and oncology. Then respiratory and inflammatory diseases. And don’t forget mental illness and retinal health. Oh, it was also the day the company launched another Humira biosimilar. 

advertisement

In other words, there was a whole lot for the company to discuss as it works to promote its breadth and build partnerships with academic researchers and other companies. 

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Gene therapy has helped boys walk. Can scientists keep it that way?
Next article： Sports medicine is finally prioritizing gender equality